Responses
Oral Plenary
Plenary V
IGCS20_1306
15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients
Compose a Response to This Article
Other responses
No responses have been published for this article.